Pathological outcomes of candidates for active surveillance of prostate cancer.
about
Relationship between initial PSA density with future PSA kinetics and repeat biopsies in men with prostate cancer on active surveillanceManagement of low (favourable)-risk prostate cancerProstate cancer managed with active surveillance: role of anatomic MR imaging and MR spectroscopic imaging.The use of exome genotyping to predict pathological Gleason score upgrade after radical prostatectomy in low-risk prostate cancer patientsOutcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH databaseImpact of immediate TRUS rebiopsy in a patient cohort considering active surveillance for favorable risk prostate cancer.Outcomes of active surveillance for men with intermediate-risk prostate cancer.Reclassification rates are higher among African American men than Caucasians on active surveillanceIs active surveillance a safe alternative in the management of localized prostate cancer? Pathological features of radical prostatectomy specimens in potential candidates for active surveillance.miR-19, miR-345, miR-519c-5p serum levels predict adverse pathology in prostate cancer patients eligible for active surveillance.Adverse Pathologic Features at Radical Prostatectomy: Effect of Preoperative Risk on Oncologic Outcomes.Identification of threshold prostate specific antigen levels to optimize the detection of clinically significant prostate cancer by magnetic resonance imaging/ultrasound fusion guided biopsy.Nonvisible tumors on multiparametric magnetic resonance imaging does not predict low-risk prostate cancer.Role of active surveillance in the management of localized prostate cancer.Applying precision medicine to the active surveillance of prostate cancer.Predictive models for worsening prognosis in potential candidates for active surveillance of presumed low-risk prostate cancer.Validation of Selection Criteria for Active Surveillance in Prostate Cancer.Active surveillance for prostate cancer compared with immediate treatment: an economic analysisActive surveillance in intermediate risk prostate cancer: is it safe? Opinion: No.Pathological findings following radical prostatectomy in patients who are candidates for active surveillance: impact of varying PSA levels.African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them?Clinically available RNA profiling tests of prostate tumors: utility and comparisonCirculating microRNA signature for the diagnosis of very high-risk prostate cancerMeasurements of cancer extent in a conservatively treated prostate cancer biopsy cohort.Active surveillance for intermediate-risk prostate cancerPathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance.Increased incidence of pathologically nonorgan confined prostate cancer in African-American men eligible for active surveillance.Should prostate-specific antigen screening be offered to asymptomatic men?The current status of active surveillance for prostate cancer.Multiparametric magnetic resonance imaging in the management and diagnosis of prostate cancer: current applications and strategies.The Mind: Focal Cryotherapy in Low-Risk Prostate Cancer: Are We Treating the Cancer or the Mind?Urinary engrailed-2 (EN2) levels predict tumour volume in men undergoing radical prostatectomy for prostate cancer.PRECISION MANAGEMENT OF LOCALIZED PROSTATE CANCER.The importance of active surveillance, and immediate re-biopsy in low-risk prostate cancer: The largest series from TurkeyA biopsy-integrated algorithm for determining Gleason 6 upgrading risk stratifies risk of active surveillance failure in prostate cancer.Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer.Value of 3-Tesla multiparametric magnetic resonance imaging and targeted biopsy for improved risk stratification in patients considered for active surveillance.Utility of Gleason pattern 4 morphologies detected on transrectal ultrasound (TRUS)-guided biopsies for prediction of upgrading or upstaging in Gleason score 3 + 4 = 7 prostate cancer.Predicting prostate biopsy outcome: artificial neural networks and polychotomous regression are equivalent models.Can Prostate-Specific Antigen Kinetics before Prostate Biopsy Predict the Malignant Potential of Prostate Cancer?
P2860
Q24627957-74C98EA7-30D5-49ED-9BB4-AB0F5D57ED05Q26996501-9324BCB5-0B3A-439E-99FA-46501E5C081FQ33964345-A14D8ACC-CF81-400D-BF87-9ACD0E6B9264Q34004995-1F89746C-24FA-4570-9BFC-10BB447D1F61Q34127059-4C46088C-E35A-4B03-8E4F-C5085B3FAC46Q34406115-343D4957-F7EF-4349-8502-B9979938CF5CQ34679207-58CFD7BC-6810-4E30-8987-87E58FE2016FQ34765233-331EB0D5-75AC-4952-B407-DBB5FFB17C52Q35173116-1D039A98-B1DF-4FC1-8B8A-19EEAF3F0AD9Q35180831-3ACF2045-CB82-4AC4-B3D4-57FA6DACCA05Q36201978-15B7FF19-318C-4654-A849-E8656DDCF173Q36386904-7E83BFFF-692A-4250-8200-877C77BBFAA6Q36387925-9A5B7D3B-0B87-44DE-9CCD-F1221F51D19CQ36520452-2FDDED70-1DDB-46AE-849F-A12C70FB7695Q36592871-67454DAE-AF40-410A-95D6-FFEC53F46917Q36757440-532E6014-F98D-4299-B64B-6705A37A20BDQ36898971-15B7D922-4B52-4442-8B32-E21764C46441Q36973544-CC03B09A-33DB-469E-8B03-1A7F0218C59CQ37037022-59039236-E901-423F-91DE-6FB2131124EAQ37085230-464498A6-A73F-45D4-882A-A08FC1B25C83Q37085854-DD93E91A-8577-4467-BC5C-95900E9E8118Q37113181-218A82A1-1EF1-4EFA-A093-C5EDA89784B8Q37281617-D5EC5671-B64E-4D51-A1ED-EDAD4761BEBEQ37368939-09632D35-A53B-4C18-8876-B0719EDB3832Q37636975-01EFFF78-184F-460B-AADC-1FB14906E6B1Q37689254-16AC0491-9B4B-42CF-A830-F49F1CD4C8DCQ37689278-AA72CF6F-B54F-4365-8200-8B116C74AD21Q37774352-3919B7FF-FEF5-4B1B-B631-A6E9A5D2795DQ38018211-7F43E4F1-D884-45C8-B9AB-1C540AED3D63Q38178850-6192799D-D28C-42E7-A673-688A14AAF83EQ38391339-36EDBEB7-D788-4C46-9BD2-07201FF492F8Q38403484-AC13FA0D-34CF-49F0-A61B-82A49B84A5A3Q39108592-162A5B5F-2071-440A-9B35-E1B0BE5B36CAQ39382734-726EFD6C-1127-4F32-9262-9E7F1FE575FDQ39387342-5ACC005F-B410-4545-8AB9-27B9A6A79A05Q39391979-5C3AF1DA-E63D-4962-AE12-DE47CDA4FE97Q39513641-7AF31BB8-0C5A-41F6-81DB-4AAB44E76FCCQ39618922-9501586B-B643-472F-818C-6FB05D6690A3Q39932994-61693851-C6C3-40E1-8AA5-8BC2A2575151Q40320507-2B4FC91C-6C25-4697-A9A2-756966BF6C9C
P2860
Pathological outcomes of candidates for active surveillance of prostate cancer.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Pathological outcomes of candidates for active surveillance of prostate cancer.
@en
Pathological outcomes of candidates for active surveillance of prostate cancer.
@nl
type
label
Pathological outcomes of candidates for active surveillance of prostate cancer.
@en
Pathological outcomes of candidates for active surveillance of prostate cancer.
@nl
prefLabel
Pathological outcomes of candidates for active surveillance of prostate cancer.
@en
Pathological outcomes of candidates for active surveillance of prostate cancer.
@nl
P2093
P1476
Pathological outcomes of candidates for active surveillance of prostate cancer.
@en
P2093
Janet E Cowan
Jeffery Simko
Marc Dall'era
Peter R Carroll
Simon L Conti
Vincent Fradet
P304
1628-33; discussion 1633-4
P356
10.1016/J.JURO.2008.11.107
P407
P577
2009-02-23T00:00:00Z